The Food and Drug Administration (FDA) yesterday issued a special import permit for Paxlovid, an oral antiviral drug developed by Pfizer Inc to treat COVID-19, and the first shipment is expected to arrive before March, the Central Epidemic Command Center (CECC) said.
Pfizer’s import permit application was approved after a specialists’ meeting at the agency yesterday morning, FDA Director Wu Shou-mei (吳秀梅) said.
Having assessed Paxlovid’s therapeutic effect, safety, risks and benefits, and considering the domestic COVID-19 situation and public health demand, the specialists agreed to grant special approval to the drug, according to Article 48-2 of the Pharmaceutical Affairs Act (藥事法), she said.
Photo: Reuters
Pfizer is required to implement a risk management plan during the special permit period to ensure the drug’s safety, she added.
Paxlovid should be administered after a diagnosis of COVID-19 and within five days of the onset of symptoms, for adults who are at high of risk developing severe illness from the virus and children aged 12 or older weighing at least 40kg with mild to moderate symptoms, she said.
The drug is administered as three tablets — two tablets of PF-07321332 (150mg) and one tablet of ritonavir (100mg) — which are packaged together to take orally twice daily for a five-day course, Wu said, adding that not following the course could affect the treatment.
PF-07321332 works by blocking the activity of an enzyme that SARS-CoV-2 needs to multiply, and ritonavir helps slow the metabolism of PF-07321332, allowing it to remain active at higher concentrations in the blood for extended periods, she said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC, said that the ministry has signed a procurement contract with Pfizer to purchase 20,000 courses of Paxlovid, and that the first batch is expected to arrive before March.
Paxlovid is the second oral antiviral COVID-19 medication to obtain a special import permit from the FDA, after the CECC on Wednesday said that a permit was issued to US drugmaker Merck’s Taiwan branch for its molnupiravir antiviral drug.
A magnitude 7.8 earthquake struck off the southern coast of Mindanao in the Philippines at 7:38am today, prompting the US Tsunami Warning System to issue an alert for neighboring countries, including Taiwan. The system issued a purple alert indicating a "tsunami threat." The potential threat zone includes Taiwan, the Philippines, Papua New Guinea, Yap and Palau. Philippine authorities were assessing the damage from the quake, with the office of civil defense seeking to verifying initial reports that 15 people had been killed and 129 injured in the region, mostly from falling debris. Arlene Hollero, disaster chief of Maasim town in the Philippines' Sarangani Province,
RESILIENCE: Taiwan plays a key role in semiconductors, energy, information infrastructure and advanced manufacturing, AIT Director Raymond Greene said Taiwan’s continued investment in deterrence and resilience remains vital, especially in uncrewed systems and other emerging technologies, American Institute in Taiwan (AIT) Director Raymond Greene said yesterday. Greene made the remarks at the annual National Strategic Summit on Supply Chain Resilience held by the Research Institute for Democracy, Society and Emerging Technology (DSET), a government-backed think tank. As Taiwan last year became the US’ fourth-largest trading partner and supply chain security is becoming more important, cooperation in emerging technologies continues to deepen between the two countries, he said. The US is committed to accelerating innovation, building key infrastructure, strengthening cooperation
The National Chungshan Institute of Science and Technology yesterday showcased its locally developed variants of the Vision 60 robotic patrol dog, which it plans to deploy on the nation’s outlying territories in the South China Sea. The variants were produced under the Joint Lab project — created by the institute and domestic companies — and assembled with domestically produced motors, lenses and artificial intelligence (AI) systems alongside licensed tech from the US, Missile and Rocket Systems Research Division deputy director Jen Kuo-kang (任國光) told the media event at a military base in Taipei’s Dazhi (大直) area. Taiwan has built up its strengths
‘GRAY ZONE’ PRESSURE: Beijing’s activities are intended to create the deceitful impression that China has jurisdiction over the area around Taiwan, the CGA said Taiwan’s rights over its territorial waters and exclusive economic zone must not be violated by any country, the Mainland Affairs Council said yesterday, adding that it will not accept any unprovoked actions. The council issued the remarks in response to the China Coast Guard conducting maritime enforcement drills near eastern Taiwan and claiming to fully exercise China’s maritime administrative law enforcement authority. The Coast Guard Administration (CGA) has been closely monitoring the situation and is taking concrete steps to defend the nation’s sovereignty and secure its waters, the council said. China has no sovereign rights over the waters off eastern
RSS